Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11931625rdf:typepubmed:Citationlld:pubmed
pubmed-article:11931625lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0056154lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:11931625lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:11931625pubmed:issue8lld:pubmed
pubmed-article:11931625pubmed:dateCreated2002-4-4lld:pubmed
pubmed-article:11931625pubmed:abstractTextThe synthesis and structure-activity relationship study of a series of compounds with heterocycles in place of the cis double bond in combretastatin A-4 (CA-4) are described. Substituted tosylmethyl isocyanides were found to be the key intermediates in construction of the heterocycles. Cytotoxicities of the heterocycle-based CA-4 analogues were evaluated against NCI-H460 and HCT-15 cancer cell lines. 3-Amino-4-methoxyphenyl and N-methyl-indol-5-yl were the best replacements for the 3-hydroxy-4-methoxyphenyl in CA-4. 4,5-Disubstituted imidazole was found to be the best for the replacement of the cis double bond in CA-4. Medicinal chemistry efforts led to the discovery of compounds 24h and 25f that were found to be 32 and 82% bioavailable, respectively, in rat. Evaluation of 24h and 25f against murine M5076 reticulum sarcoma in mice revealed that both compounds were orally efficacious with an increase in life span of 38.5 and 40.5%, respectively.lld:pubmed
pubmed-article:11931625pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931625pubmed:languageenglld:pubmed
pubmed-article:11931625pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931625pubmed:citationSubsetIMlld:pubmed
pubmed-article:11931625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931625pubmed:statusMEDLINElld:pubmed
pubmed-article:11931625pubmed:monthAprlld:pubmed
pubmed-article:11931625pubmed:issn0022-2623lld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:HuiYu-HuaYHlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:LiQunQlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:WoodsKeith...lld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:BarrKenneth...lld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:CredoR...lld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:MarshKennanKlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:FrostDavidDlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:ShamHing LHLlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:WangLeLlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:McCroskeyRich...lld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:HannickSteven...lld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:GherkeLauraLlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:WarnerRobertRlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:LeeJang YJYlld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:Zielinski-Moz...lld:pubmed
pubmed-article:11931625pubmed:authorpubmed-author:RosenbergSaul...lld:pubmed
pubmed-article:11931625pubmed:issnTypePrintlld:pubmed
pubmed-article:11931625pubmed:day11lld:pubmed
pubmed-article:11931625pubmed:volume45lld:pubmed
pubmed-article:11931625pubmed:ownerNLMlld:pubmed
pubmed-article:11931625pubmed:authorsCompleteYlld:pubmed
pubmed-article:11931625pubmed:pagination1697-711lld:pubmed
pubmed-article:11931625pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:meshHeadingpubmed-meshheading:11931625...lld:pubmed
pubmed-article:11931625pubmed:year2002lld:pubmed
pubmed-article:11931625pubmed:articleTitlePotent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.lld:pubmed
pubmed-article:11931625pubmed:affiliationGlobal Pharmaceutical R & D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6101, USA. le.wang@abbott.comlld:pubmed
pubmed-article:11931625pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11931625lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11931625lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11931625lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11931625lld:pubmed